vs

Side-by-side financial comparison of Arcellx, Inc. (ACLX) and VerifyMe, Inc. (VRME). Click either name above to swap in a different company.

Arcellx, Inc. is the larger business by last-quarter revenue ($8.1M vs $5.0M, roughly 1.6× VerifyMe, Inc.). VerifyMe, Inc. runs the higher net margin — -66.7% vs -766.0%, a 699.3% gap on every dollar of revenue. On growth, VerifyMe, Inc. posted the faster year-over-year revenue change (-7.4% vs -79.3%). Over the past eight quarters, VerifyMe, Inc.'s revenue compounded faster (-5.2% CAGR vs -24.6%).

Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.

VerifyMe, Inc. is a technology provider specializing in identity verification, anti-counterfeiting, and brand protection solutions. Its offerings include secure authentication tools, supply chain traceability systems, and customer engagement platforms, serving consumer goods, pharmaceutical, and retail sectors across North America and select global markets.

ACLX vs VRME — Head-to-Head

Bigger by revenue
ACLX
ACLX
1.6× larger
ACLX
$8.1M
$5.0M
VRME
Growing faster (revenue YoY)
VRME
VRME
+71.9% gap
VRME
-7.4%
-79.3%
ACLX
Higher net margin
VRME
VRME
699.3% more per $
VRME
-66.7%
-766.0%
ACLX
Faster 2-yr revenue CAGR
VRME
VRME
Annualised
VRME
-5.2%
-24.6%
ACLX

Income Statement — Q1 FY2025 vs Q3 FY2025

Metric
ACLX
ACLX
VRME
VRME
Revenue
$8.1M
$5.0M
Net Profit
$-62.3M
$-3.4M
Gross Margin
41.2%
Operating Margin
-847.6%
-68.2%
Net Margin
-766.0%
-66.7%
Revenue YoY
-79.3%
-7.4%
Net Profit YoY
-765.1%
-38.4%
EPS (diluted)
$-1.13
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLX
ACLX
VRME
VRME
Q3 25
$5.0M
Q2 25
$4.5M
Q1 25
$8.1M
$4.5M
Q4 24
$15.3M
Q3 24
$26.0M
$5.4M
Q2 24
$27.4M
$5.4M
Q1 24
$39.3M
$5.8M
Q4 23
$63.1M
$8.7M
Net Profit
ACLX
ACLX
VRME
VRME
Q3 25
$-3.4M
Q2 25
$-291.0K
Q1 25
$-62.3M
$-571.0K
Q4 24
$-47.1M
Q3 24
$-25.9M
$-2.4M
Q2 24
$-27.2M
$-346.0K
Q1 24
$-7.2M
$-553.0K
Q4 23
$19.8M
$2.0K
Gross Margin
ACLX
ACLX
VRME
VRME
Q3 25
41.2%
Q2 25
35.2%
Q1 25
33.4%
Q4 24
Q3 24
34.9%
Q2 24
39.1%
Q1 24
39.2%
Q4 23
33.0%
Operating Margin
ACLX
ACLX
VRME
VRME
Q3 25
-68.2%
Q2 25
-7.1%
Q1 25
-847.6%
-13.3%
Q4 24
-348.2%
Q3 24
-129.1%
-52.8%
Q2 24
-127.8%
-10.0%
Q1 24
-40.3%
-11.2%
Q4 23
23.8%
0.8%
Net Margin
ACLX
ACLX
VRME
VRME
Q3 25
-66.7%
Q2 25
-6.4%
Q1 25
-766.0%
-12.8%
Q4 24
-308.4%
Q3 24
-99.4%
-44.6%
Q2 24
-99.3%
-6.5%
Q1 24
-18.3%
-9.6%
Q4 23
31.4%
0.0%
EPS (diluted)
ACLX
ACLX
VRME
VRME
Q3 25
$-0.26
Q2 25
$-0.02
Q1 25
$-1.13
$-0.05
Q4 24
$-0.87
Q3 24
$-0.48
$-0.23
Q2 24
$-0.51
$-0.03
Q1 24
$-0.14
$-0.05
Q4 23
$0.42
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLX
ACLX
VRME
VRME
Cash + ST InvestmentsLiquidity on hand
$543.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$416.9M
$11.1M
Total Assets
$648.1M
$13.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLX
ACLX
VRME
VRME
Q3 25
Q2 25
Q1 25
$543.3M
Q4 24
$587.4M
Q3 24
$574.3M
$2.6M
Q2 24
$516.7M
$2.9M
Q1 24
$573.9M
$2.8M
Q4 23
$702.0M
$3.0M
Total Debt
ACLX
ACLX
VRME
VRME
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$500.0K
Q2 24
$600.0K
Q1 24
$800.0K
Q4 23
$875.0K
Stockholders' Equity
ACLX
ACLX
VRME
VRME
Q3 25
$11.1M
Q2 25
$14.4M
Q1 25
$416.9M
$14.6M
Q4 24
$454.8M
Q3 24
$483.0M
$10.3M
Q2 24
$487.2M
$12.3M
Q1 24
$496.6M
$12.4M
Q4 23
$485.4M
Total Assets
ACLX
ACLX
VRME
VRME
Q3 25
$13.3M
Q2 25
$17.2M
Q1 25
$648.1M
$17.1M
Q4 24
$711.3M
Q3 24
$764.9M
$14.8M
Q2 24
$734.3M
$17.5M
Q1 24
$779.7M
$17.9M
Q4 23
$825.1M
$20.7M
Debt / Equity
ACLX
ACLX
VRME
VRME
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.05×
Q2 24
0.05×
Q1 24
0.06×
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLX
ACLX
VRME
VRME
Operating Cash FlowLast quarter
$-63.1M
$243.0K
Free Cash FlowOCF − Capex
$-63.9M
FCF MarginFCF / Revenue
-786.4%
Capex IntensityCapex / Revenue
9.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-122.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLX
ACLX
VRME
VRME
Q3 25
$243.0K
Q2 25
$710.0K
Q1 25
$-63.1M
$-404.0K
Q4 24
$-46.0M
Q3 24
$30.7M
$-10.0K
Q2 24
$-36.2M
$372.0K
Q1 24
$-31.9M
$-60.0K
Q4 23
$58.2M
$843.0K
Free Cash Flow
ACLX
ACLX
VRME
VRME
Q3 25
Q2 25
Q1 25
$-63.9M
Q4 24
$-47.5M
Q3 24
$28.4M
$-12.0K
Q2 24
$-39.5M
$369.0K
Q1 24
$-38.3M
$-62.0K
Q4 23
$53.0M
$840.0K
FCF Margin
ACLX
ACLX
VRME
VRME
Q3 25
Q2 25
Q1 25
-786.4%
Q4 24
-311.3%
Q3 24
109.2%
-0.2%
Q2 24
-144.1%
6.9%
Q1 24
-97.7%
-1.1%
Q4 23
83.9%
9.6%
Capex Intensity
ACLX
ACLX
VRME
VRME
Q3 25
Q2 25
Q1 25
9.6%
Q4 24
9.8%
Q3 24
8.8%
0.0%
Q2 24
11.7%
0.1%
Q1 24
16.4%
0.0%
Q4 23
8.4%
0.0%
Cash Conversion
ACLX
ACLX
VRME
VRME
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
2.94×
421.50×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACLX
ACLX

Segment breakdown not available.

VRME
VRME

Proactive Services$4.2M83%
Other$869.0K17%

Related Comparisons